1 May 2023 false No description of principal activity Taxfiler 2024.6 SC476268business:PrivateLimitedCompanyLtd2023-05-012024-04-30 SC4762682023-04-30 SC4762682023-05-012024-04-30 SC476268business:AuditExemptWithAccountantsReport2023-05-012024-04-30 SC476268business:FilletedAccounts2023-05-012024-04-30 SC4762682024-04-30 SC476268business:Director12023-05-012024-04-30 SC476268business:RegisteredOffice2023-05-012024-04-30 SC4762682023-04-30 SC476268core:WithinOneYear2024-04-30 SC476268core:WithinOneYear2023-04-30 SC476268core:AfterOneYear2024-04-30 SC476268core:AfterOneYear2023-04-30 SC476268core:ShareCapitalcore:PreviouslyStatedAmount2024-04-30 SC476268core:ShareCapitalcore:PreviouslyStatedAmount2023-04-30 SC476268core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-04-30 SC476268core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-04-30 SC476268core:PreviouslyStatedAmount2024-04-30 SC476268core:PreviouslyStatedAmount2023-04-30 SC476268business:SmallEntities2023-05-012024-04-30 SC476268countries:Scotland2023-05-012024-04-30 SC476268core:PlantMachinery2023-05-012024-04-30 SC476268core:ComputerEquipment2023-05-012024-04-30 SC476268core:IntangibleAssetsOtherThanGoodwill2023-04-30 SC476268core:IntangibleAssetsOtherThanGoodwill2024-04-30 SC476268core:IntangibleAssetsOtherThanGoodwill2023-05-012024-04-30 SC476268core:PlantMachinery2023-04-30 SC476268core:ComputerEquipment2023-04-30 SC476268core:PlantMachinery2024-04-30 SC476268core:ComputerEquipment2024-04-30 SC476268business:OrdinaryShareClass12023-05-012024-04-30 SC476268business:OrdinaryShareClass12022-05-012023-04-30 SC4762682022-05-012023-04-30 iso4217:GBP xbrli:shares xbrli:pure
Company Registration No. SC476268 (Scotland)
The Antibody Company Limited Unaudited accounts for the year ended 30 April 2024
The Antibody Company Limited Unaudited accounts Contents
Page
- 2 -
The Antibody Company Limited Company Information for the year ended 30 April 2024
Director
E Wagner
Company Number
SC476268 (Scotland)
Registered Office
10 Church Avenue Newmains Lanarkshire ML2 9BH
Accountants
Assenti & Noble Ltd 18 Mosshead Road Bearsden Glasgow G61 3HN
- 3 -
The Antibody Company Limited Statement of financial position as at 30 April 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Intangible assets
7,592 
9,111 
Tangible assets
28,622 
34,000 
36,214 
43,111 
Current assets
Inventories
45,000 
- 
Debtors
33,066 
17,919 
Cash at bank and in hand
77,874 
38,598 
155,940 
56,517 
Creditors: amounts falling due within one year
(147,723)
(45,931)
Net current assets
8,217 
10,586 
Total assets less current liabilities
44,431 
53,697 
Creditors: amounts falling due after more than one year
(37,876)
(44,839)
Net assets
6,555 
8,858 
Capital and reserves
Called up share capital
1,000 
1,000 
Profit and loss account
5,555 
7,858 
Shareholders' funds
6,555 
8,858 
For the year ending 30 April 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 14 January 2025 and were signed on its behalf by
E Wagner Director Company Registration No. SC476268
- 4 -
The Antibody Company Limited Notes to the Accounts for the year ended 30 April 2024
1
Statutory information
The Antibody Company Limited is a private company, limited by shares, registered in Scotland, registration number SC476268. The registered office is 10 Church Avenue, Newmains, Lanarkshire, ML2 9BH.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention.
Presentation currency
The accounts are presented in £ sterling.
Intangible fixed assets
Intangible fixed assets comprising purchased licences are capitalised and written off on a straight line basis over a 10 year period. Provision is made for any impairment in value.
Tangible fixed assets policy
Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Plant & machinery
between 2 & 5 years straight line
Computer equipment
4 years straight line
4
Intangible fixed assets
Other 
£ 
Cost
At 1 May 2023
15,183 
At 30 April 2024
15,183 
Amortisation
At 1 May 2023
6,072 
Charge for the year
1,519 
At 30 April 2024
7,591 
Net book value
At 30 April 2024
7,592 
At 30 April 2023
9,111 
- 5 -
The Antibody Company Limited Notes to the Accounts for the year ended 30 April 2024
5
Tangible fixed assets
Plant & machinery 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 May 2023
154,879 
21,355 
176,234 
Additions
6,684 
3,665 
10,349 
At 30 April 2024
161,563 
25,020 
186,583 
Depreciation
At 1 May 2023
121,506 
20,728 
142,234 
Charge for the year
14,278 
1,449 
15,727 
At 30 April 2024
135,784 
22,177 
157,961 
Net book value
At 30 April 2024
25,779 
2,843 
28,622 
At 30 April 2023
33,373 
627 
34,000 
6
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
Trade debtors
25,549 
12,552 
Accrued income and prepayments
2,480 
330 
Other debtors
5,037 
5,037 
33,066 
17,919 
7
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Bank loans and overdrafts
5,833 
10,000 
VAT
5,469 
1,614 
Obligations under finance leases and hire purchase contracts
8,809 
9,742 
Trade creditors
10,344 
5,653 
Taxes and social security
800 
1,060 
Other creditors
48,844 
15,133 
Loans from directors
24 
4 
Accruals
49,600 
850 
Deferred income
18,000 
1,875 
147,723 
45,931 
8
Creditors: amounts falling due after more than one year
2024 
2023 
£ 
£ 
Bank loans
21,727 
21,670 
Obligations under finance leases and hire purchase contracts
16,149 
23,169 
37,876 
44,839 
- 6 -
The Antibody Company Limited Notes to the Accounts for the year ended 30 April 2024
9
Share capital
2024 
2023 
£ 
£ 
Allotted, called up and fully paid:
1,000 Ordinary shares of £1 each
1,000 
1,000 
10
Average number of employees
During the year the average number of employees was 5 (2023: 6).
- 7 -